$CRVS
Corvus Pharmaceuticals, Inc.
XNAS•Health Care•Pharmaceutical Preparations
$10.90
▼-0.27%-$0.030
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateCorvus Pharmaceuticals, Inc.
XNAS•Health Care•Pharmaceutical Preparations
Why is CRVS down today? It is at $10.90 (-0.27%), and our scanner flagged it 88 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment CRVS spikes, and full due diligence on CRVS — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $CRVS 88 times in the last 30 days. Create a free account to track $CRVS, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on CRVS from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for CRVS today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystCorvus Pharmaceuticals, Inc.: Q2 FY2026 results, three months to Jun 30, 2026, from an SEC filing. Read it →Latest filingSC 13GPassive 5%+ stake disclosedAug 7, 2026 · 58 days agoAcross every filing on file, supply equal to 0.00% of the tradeable float is in play - 0.00% more can still be issued.
At-the-market (ATM) offering active — the company can keep selling new shares into the market over time (ongoing)
0 new shares · At-the-market (ATM) program — sells new shares into the market gradually over time · About $0 in size · Priced at $16.9/share
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Moore David Scott Director | Bought (open market) | +22K 0.03% of company | n/a | 22K | $250K at $11.53 | Jun 11, 26 |
Miller Richard A Md Officer | Bought (open market) | +7K | added 0.6% | 1.20M | $83K at $12.01 | May 18, 26 |
Thompson Peter A. Director | Other | 210K 0.2% of company | n/a | 210K | $202K at $0.960 | Jan 28, 26 |
Thompson Peter A. Director | Sold (automatic/other) | -1.18M 1.4% of company | sold 14% | 7.17M | $4.9M at $4.16 | Jun 27, 25 |
Thompson Peter A. Director | Other | 1.40M 1.7% of company | added 20% | 8.34M | $4.9M at $3.50 | Jun 27, 25 |
Orbimed Advisors Llc Director | Sold (automatic/other) | -1.18M 1.4% of company | sold 14% | 7.17M | $4.9M at $4.16 | Jun 27, 25 |
Orbimed Advisors Llc Director | Other | 1.40M 1.7% of company | added 20% | 8.34M | $4.9M at $3.50 | Jun 27, 25 |
Jones William Benton Officer | Other | 19K 0.02% of company | added 13% | 173K | $68K at $3.50 | Jun 4, 25 |
Miller Richard A Md Officer | Other | 559K 0.7% of company | added 97% | 1.14M | $2.0M at $3.50 | May 7, 25 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in pharmaceutical preparations, closest in size first.
Here is the latest on CRVS from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for CRVS today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
CRVS last traded at $10.90, down 0.27% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Corvus Pharmaceuticals, Inc. (CRVS) is next expected to report earnings on Tuesday, November 3, 2026, about 30 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The CRVS Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged CRVS 88 times in the last 30 days.
CRVS (Corvus Pharmaceuticals, Inc.) trades on XNAS, with a market cap of about $917M in the Pharmaceutical Preparations sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge CRVS for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$CRVS discussion
Sign in to ask a question or join the discussion.